In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Giulia PintonDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
Elia BariDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.ORCID 0000-0003-0241-0620 Silvia FallariniDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.ORCID 0000-0001-8871-7417 Valentina GigliottiDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
Veronica De GiorgisDepartment of Translational Medicine, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
Fausto ChiazzaDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.ORCID 0000-0001-7273-0051 Maria Luisa TorreDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.ORCID 0000-0001-8062-6836 Marcello ManfrediDepartment of Translational Medicine, University of Piemonte Orientale (UPO), 28100 Novara, Italy.ORCID 0000-0003-0632-5618 Laura MoroDepartment of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), 28100 Novara, Italy.
Funding
2022CBYF9P - CUP: C53D23004690001, which has received funding from NextGeneration EU - MUR M4C2- PRIN 2022 naBando Fondazione Oncologica Valdostana 2024 naBando Ricerca UPO 2022 (MUR-DM 737/2021 of PNR and Compagnia San Paolo) na
6 · The paper itselfAbstract
We previously demonstrated that in BAP1-proficient pleural mesothelioma cells,
Indexed as
Enhancer of Zeste Homolog 2 ProteinExtracellular VesiclesMesotheliomaNeutrophilsB7-H1 AntigenCell Line, TumorCell ProliferationGPI-Linked ProteinsHumansMesothelinPhenotypeSpheroids, CellularTetraspanin 30T-LymphocytesTumor MicroenvironmentTumor Suppressor ProteinsB7-H1 AntigenCD274 protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanGPI-Linked ProteinsMesothelinMSLN protein, humanTetraspanin 30Tumor Suppressor Proteinsextracellular vesiclesEZH2 inhibitionMSLN and PD-L1 expressionneutrophilspleural mesotheliomatazemetostat (EPZ-6438)
Identifiers
PMID41226368
PMCPMC12607341
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390